SCHEMBL29520286

SCHEMBL29520286

CCNC(=O)c1cc(F)ccc1N

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.56
FADS1 O60427 1/20 0.50
NOS2 P35228 1/20 0.43
HDAC1 Q13547 5/20 0.42
BRAF P15056 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
CA2 P00918 2/20 0.42
CA4 P22748 2/20 0.42
LMNA P02545 1/20 0.41
JAK2 O60674 1/20 0.40
JAK1 P23458 1/20 0.40
TYK2 P29597 1/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
HDAC2 Q92769 1/20 0.39
MPO P05164 1/20 0.39
HDAC3 O15379 1/20 0.39
CES2 O00748 1/20 0.39
CES1 P23141 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13753884 1.00 KEAP1 (0.56) KEAP1FADS1NOS2HDAC1BRAF
SCHEMBL13181106 0.87 HDAC1 (0.45) KEAP1HDAC1L3MBTL1CA2CA4
SCHEMBL6366517 0.84 HTT (0.55) KEAP1FADS1HDAC1CA2CA4
SCHEMBL13753059 0.83 CES2 (0.55) L3MBTL1CA2CA4LMNACES2
SCHEMBL24210299 0.82 KEAP1 (0.63) KEAP1FADS1HDAC1BRAFKDM4E
SCHEMBL15630978 0.82 KEAP1 (0.59) KEAP1FADS1HDAC1CA2KDM4E
SCHEMBL15402062 0.81 CFTR (0.51) KEAP1FADS1HDAC1BRAFJAK2
SCHEMBL6887760 0.81 NAAA (0.48) NOS2HDAC1BRAFCA2LMNA
SCHEMBL13753816 0.81 HPGD (0.49) NOS2LMNAKDM4EALDH1A1HPGD
SCHEMBL1911846 0.81 P2RX7 (0.44) L3MBTL1CA2CA4LMNACES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12479830-B2 Homopiperazinyl and homopiperidinyl quinazolin-4(3H)-one derivatives having multimodal activity against pain ESTEVE PHARMACEUTICALS, S.A. (ES) 2025-11-25 US disclosed
CN-114502549-B Homopiperazinyl and homopiperidinyl quinazolin-4 (3H) -one derivatives having multimodal activity against pain 埃斯特韦制药股份公司 2024-10-25 CN disclosed
US-20220380345-A1 HOMOPIPERAZINYL AND HOMOPIPERIDINYL QUINAZOLIN-4(3H)-ONE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN ESTEVE PHARMACEUTICALS, S.A. (ES) 2022-12-01 US disclosed
EP-4041391-A1 HOMOPIPERAZINYL AND HOMOPIPERIDINYL QUINAZOLIN-4(3H)-ONE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN ESTEVE PHARMACEUTICALS, S.A. (ES) 2022-08-17 EP disclosed
CN-114502549-A Homopiperazinyl and homopiperidinyl quinazolin-4 (3H) -one derivatives having multimodal activity against pain 埃斯特韦制药股份公司 2022-05-13 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12479830-B2 Homopiperazinyl and homopiperidinyl quinazolin-4(3H)-one derivatives having multimodal activity against pain OPRD1, SIGMAR1, OPRK1 KEAP1 3384/4885FADS1 4642/4885NOS2 2193/4885
US-20220380345-A1 HOMOPIPERAZINYL AND HOMOPIPERIDINYL QUINAZOLIN-4(3H)-ONE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN OPRD1, SIGMAR1, OPRK1 KEAP1 3384/4885FADS1 4642/4885NOS2 2193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.